IAS News and Literature Updates:
January/February 2018
From the President's Desk:
Yuji Matsuzawa

The cholesteryl ester transfer protein (CETP) promotes the transfer of cholesteryl esters (CE) from high density lipoproteins (HDL) to apoB-containing lipoproteins, one of key steps of reverse cholesterol transport and its inhibition thus increases the concentration of HDL cholesterol while decreasing the cholesterol level in apoB-containing lipoproteins. The concept that CETP inhibition may prevent atherosclerosis because of these effects has been investigated, with varying results.
Cardiovascular clinical outcomes studies of the first three CETP inhibitors were terminated because of either increased mortality or futility despite marked increases in HDL-cholesterol, although in each case there were problems with either serious adverse effects unrelated to CETP (torcetrapib) or to trials that may have terminated too early (dalcetrapib and evacetrapib). A fourth trial (REVEAL) using the CETP inhibitor anacetrapib was larger and much longer and showed that inhibition of CETP does reduce coronary events (the primary endpoint of the trial), although the benefit may have been the consequence of a reduction of cholesterol levels in the atherogenic apoB-containing lipoproteins rather than an increase in HDL levels. Anacetrapib is retained in the body for years after therapy and, although there were no serious adverse effects of the drug in the REVEAL trial, a decision was made to not develop the agent further. So, the future of CETP inhibition as a strategy to reduce cardiovascular events in statin-treated patients remains uncertain.

> Complete Article <

organizing the APPLY NOW: Deadline Extended!!

IAS Visiting Fellowship Opportunities
New Application Deadline: March 15, 2018
3 - Month Visiting Fellowship Award $5,000
• 6 - Month Visiting Fellowship Award $8,000

For the Flyer Click Here
For more information Click Here
Also included in this Newsletter:

XVIII International Symposium on Atherosclerosis
Toronto, Canada
June 9-12, 2018


In the News: 

Remodeling of Plasma High Density Lipoproteins: HDL Remnant Formation—Does Scavenger Receptor Class B Type 1 Nibble or Gobble HDL-Lipids?

By: Baiba K Gillard and Henry J. Pownall

There are several key lipid risk factors for cardiovascular disease (CVD)-elevated plasma levels of total cholesterol, LDL-cholesterol, and triglycerides. Moreover, the quality of lipoproteins is also important with small LDL and HDL (HDL3) particles being associated with more CVD. There is continued interest in mechanisms that regulate plasma levels of high density lipoprotein-cholesterol (HDL-C), which is a negative risk factor for cardiovascular disease. The selective trans-hepatic extraction of high density lipoprotein cholesteryl esters (CE) via the scavenger receptor class B type 1 (SR-B1), is a major route for the removal of plasma HDL-C.

> View Complete Commentary

PCSK9 Inhibitors and Lipoprotein(a) Lowering – More to It Than Meets the Eye

By: Michael D Shapiro and Sergio Fazio

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Low-density lipoprotein (LDL) cholesterol (LDL-C) is widely accepted as the most important causal risk factor for ASCVD. Recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) was identified as a central protein in the trafficking of plasma LDL. Whereas the canonical regulatory proteins of cholesterol homeostasis are strictly intracellular (SREBP, LXR, HMG-CoA R, ACAT, IDOL, and LDLR), remarkably PCSK9 is secreted in low abundance from hepatocytes into the circulation, from where it exerts dominant control over cellular cholesterol homeostasis.

> View Complete Commentary


February 27 - March 1, 2018

Philippine Lipid and Atherosclerosis Society (PLAS); The 11th APSAVD Congress (2018) Annual Scientific Meeting on Addressing Regional Diversity in Atherosclerosis and Vascular Disease
 Iloilo City, Philippines

View Meeting Information

April 13-14, 2018

Course of Dyslipidemia, organized by the Chilean Working Group on Atherosclerosis and the Fundación Lucas Sierra
Viña del Mar, Chile

View Meeting Information

For a complete listing of all Member Society Meetings and educational activities

Please Click Here


The IAS wishes to thank all the supporters which have generously offered grants to the IAS for the development of its many activities and in support of its mission: Aegerion Pharmaceuticals, Amgen, Inc., Amgen (Europe) GmbH, Amryt, Daiichi Sankyo Co., Ltd., Fondazione Giovanni Lorenzini, Ono Pharmaceutical Co., Ltd., OSLA - Oman Society of Lipids and Atherosclerosis, Otsuka Pharmaceutical Co., Ltd., Pfizer, Sanofi and Regeneron, and Weill Cornell Medical College.

>> Back To Top <<
IAS Newsletter Editors
Website Editorial Board
Scott M. Grundy, MD, PhD
Dallas, TX, USA

Associate Editors
Stefano Bellosta, PhD
Milan, Italy
Emanuela Folco, PhD
Milan, Italy
Ann Jackson, MBA
Houston, TX, USA

Website & Newsletter Editors
Elena Colombo
Milan, Italy
Yelonda Williams, BA
Dallas, TX, USA


You are a valued member of the International Atherosclerosis Society. You are receiving this email because you opted in at our website - www.athero.org

Unsubscribe <<Email Address>> from this list.

Our mailing address is:
International Atherosclerosis Society
Fondazione Giovanni Lorenzini Medical Science Foundation
viale Piave 35
Milan, Italy 20129

Add us to your address book

Copyright (C) 2018 International Atherosclerosis Society All rights reserved.

Forward this email to a friend
Update your profile